Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PCSA
stocks logo

PCSA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.050
-93.24%
--
--
-0.060
-80%
--
--
-0.050
-80%
Estimates Revision
The market is revising No Change the revenue expectations for Processa Pharmaceuticals, Inc. (PCSA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 57.86%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+57.86%
In Past 3 Month
Wall Street analysts forecast PCSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCSA is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast PCSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCSA is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.271
sliders
Low
1.00
Averages
1.00
High
1.00
Current: 0.271
sliders
Low
1.00
Averages
1.00
High
1.00
H.C. Wainwright
Raghuram Selvaraju
Buy
downgrade
$2 -> $1
2025-09-02
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$2 -> $1
2025-09-02
downgrade
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Processa Pharmaceuticals to $1 from $2 and keeps a Buy rating on the shares. The firm cites equity dilution from the strategic investment for the target cut.
H.C. Wainwright
Buy
downgrade
$6 -> $2
2025-06-30
Reason
H.C. Wainwright
Price Target
$6 -> $2
2025-06-30
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Processa Pharmaceuticals to $2 from $6 and keeps a Buy rating on the shares after the company recently announced that it had raised a total of $7M in gross proceeds from an equity financing involving the sale of common shares, pre-funded warrants and warrants to purchase common stock. The equity financing lengthens the runway through key clinical development milestone, but the firm is lowering its price target to account for dilution, the analyst noted.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$6
2024-12-05
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$6
2024-12-05
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Processa Pharmaceuticals Inc (PCSA.O) is -1.09, compared to its 5-year average forward P/E of -3.23. For a more detailed relative valuation and DCF analysis to assess Processa Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.23
Current PE
-1.09
Overvalued PE
0.81
Undervalued PE
-7.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PCSA News & Events

Events Timeline

(ET)
2025-08-07
08:40:54
Processa secures strategic investment, evaluates crypto strategy
select
2025-07-01 (ET)
2025-07-01
09:07:35
Processa terminates license agreement for PCS3117
select
2025-06-17 (ET)
2025-06-17
12:31:14
Processa sells 28M shares at 25c in public offering
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-24NASDAQ.COM
Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading

  • Butterfly Network Update: Butterfly Network's shares rose 6.04% after announcing CEO Joseph DeVivo and Interim CFO Megan Carlson will participate in investor meetings at the Evercore Healthcare Conference on December 2, 2025, highlighting their handheld ultrasound technology.

  • Citius Pharmaceuticals Collaboration: Citius Pharmaceuticals saw a 7.90% increase in shares after announcing a collaboration with Verix to utilize its AI-powered Tovana platform for the U.S. commercialization of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma.

  • General Market Activity: ProQR Therapeutics, Perrigo Company, and Tempest Therapeutics also experienced share price increases, with Tempest announcing plans to acquire CAR-T programs to enhance its pipeline.

  • Other Stocks Performance: Iterum Therapeutics and Processa Pharmaceuticals had minor share price movements without any new updates, reflecting varied investor sentiment in the biotech sector.

[object Object]
Preview
9.0
11-05Newsfilter
Processa Pharmaceuticals to Present Poster on Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

  • Processa Pharmaceuticals Presentation: Processa Pharmaceuticals announced that their abstract on PCS499 for treating Focal Segmental Glomerulosclerosis (FSGS) has been accepted for presentation at the ASN Kidney Week 2025 in Houston, Texas, scheduled for November 7, 2025.

  • PCS499 Overview: PCS499, an analog of pentoxifylline, shows a favorable safety profile that may allow for higher dosing and improved therapeutic benefits for patients with FSGS, a serious kidney condition with no FDA-approved treatments.

  • Adaptive Study Design: The adaptive Phase 2/3 study aims to optimize dosing and expedite regulatory approval, addressing the urgent need for safer and more effective therapies for FSGS patients.

  • Company Focus: Processa Pharmaceuticals is dedicated to developing Next Generation Cancer therapies and is also exploring strategic partnerships for non-oncology assets to enhance their portfolio and patient care.

[object Object]
Preview
2.0
10-08NASDAQ.COM
Biotech Stocks Soar in After-Hours Trading: PCSA, PALI, and QTTB Top the Charts in Volume and Speculation

  • Processa Pharmaceuticals Surge: Processa Pharmaceuticals Inc. (PCSA) saw a significant after-hours gain of 40.3%, closing at $0.51, driven by speculative momentum and unusually high trading volume of over 200 million shares.

  • Palisade Bio's Volatility: Palisade Bio Inc. (PALI) experienced an 11.9% rise in after-hours trading to $1.88, following a recent $138 million public offering and positive clinical trial results for its ulcerative colitis treatment.

  • Q32 Bio's Speculative Rise: Q32 Bio Inc. (QTTB) rose 26.6% in after-hours trading to $3.19, with the increase attributed to speculative trading ahead of its upcoming earnings report, despite no new company announcements.

  • Market Activity Overview: The sharp gains in these small-cap biotech stocks reflect a mix of speculative trading, clinical updates, and capital market activities, highlighting the volatility in the biotech sector.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Processa Pharmaceuticals Inc (PCSA) stock price today?

The current price of PCSA is 0.2712 USD — it has increased 1.5 % in the last trading day.

arrow icon

What is Processa Pharmaceuticals Inc (PCSA)'s business?

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.

arrow icon

What is the price predicton of PCSA Stock?

Wall Street analysts forecast PCSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCSA is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Processa Pharmaceuticals Inc (PCSA)'s revenue for the last quarter?

Processa Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Processa Pharmaceuticals Inc (PCSA)'s earnings per share (EPS) for the last quarter?

Processa Pharmaceuticals Inc. EPS for the last quarter amounts to -0.07 USD, decreased -93.20 % YoY.

arrow icon

What changes have occurred in the market's expectations for Processa Pharmaceuticals Inc (PCSA)'s fundamentals?

The market is revising No Change the revenue expectations for Processa Pharmaceuticals, Inc. (PCSA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 57.86%.
arrow icon

How many employees does Processa Pharmaceuticals Inc (PCSA). have?

Processa Pharmaceuticals Inc (PCSA) has 10 emplpoyees as of December 05 2025.

arrow icon

What is Processa Pharmaceuticals Inc (PCSA) market cap?

Today PCSA has the market capitalization of 15.36M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free